SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2016 / Cilt: 27 - Sayı: 3

Emerging therapeutics and relevant targets for chronic Hepatitis B

Il Han SONG
Pages
210–215
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review discusses emerging therapeutics and relevant targets in the management of chronic hepatitis B

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic hepatitis B virus (HBV) infection is a global health problem for the pursuit of complete virus eradication and immunity acquisition to prevent liver disease progression.
📊
Key Findings & Data:Currently, interferon-alpha, with the underlying mechanism of host immunomodulation, and nucleos(t)ide analogs, with the underlying mechanism of inhibition of viral replication, are used for the treatment of patients with chronic hepatitis B.
💡
Conclusion & Impact:This review discusses emerging therapeutics and relevant targets in the management of chronic hepatitis B
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Chronic hepatitis B virus (HBV) infection is a global health problem for the pursuit of complete virus eradication and immunity acquisition to prevent liver disease progression. Currently, interferon-alpha, with the underlying mechanism of host immunomodulation, and nucleos(t)ide analogs, with the underlying mechanism of inhibition of viral replication, are used for the treatment of patients with chronic hepatitis B. Despite remarkable improvement in the virological, serological, biochemical, and histological response to current therapeutics, we are still far from meeting the therapeutic goals, e.g., clearance of HBV DNA/covalently closed circular DNA (cccDNA) in the serum/liver tissue and seroconversion of hepatitis B surface antigen (HBsAg) to anti-HBs in the present antiviral era. Recently, HBV replication cycle-related, viral RNA interference-based, and host immune-mediated therapeutic targets and relevant anti-HBV agents have been newly introduced and investigated in the preclinical and clinical fields. This review discusses emerging therapeutics and relevant targets in the management of chronic hepatitis B

🔖

Cite This Article

SONG, I. H. (2016). Emerging therapeutics and relevant targets for chronic Hepatitis B. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 3, 210–215. https://ajindex.com/articles/409416

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol- ogy 2009; 50: 661-2. [CrossRef] European Association For The Study Of The Liver. EASL Clinical practice guidelines: Management of chronic hepatitis B virus in- fection. EASL. J Hepatol 2012; 57: 167-85. [CrossRef] Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepa- tol Int 2008; 2: 263-83. [CrossRef] Wu X, Jia J, You H. Thymosin alpha-1 treatment in chronic hepati- tis B. Expert Opin Biol Ther 2015; 15(Suppl 1): S129-32. [CrossRef] Chan HL, Ahn SH, Chang TT, et al. Peginterferon Lambda for the Treatment of HBeAg-Positive Chronic Hepatitis B: A Randomized Phase 2b Study (LIRA-B). J Hepatol 2015.
  2. Yan H, Peng B, Liu Y, et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determi- nants on sodium taurocholate cotransporting polypeptide. J Virol 2014; 88: 3273-84. [CrossRef] Sohn JA, Litwin S, Seeger C. Mechanism for cccDNA synthesis in hepadnaviruses. PLoS One 2009; 4:e8093. [CrossRef] Pollack JR, Ganem D. An RNA stem-loop structure directs hepati- tis B virus genomic RNA encapsidation. J Virol 1993; 67: 3254-63.
  3. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of co- valently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-60. [CrossRef] Volz T, Allweiss L, Ben M, et al. The entry inhibitor Myrcludex B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861- 7. [CrossRef] Lempp FA, Urban S. Inhibitors of hepatitis B virus attachment and entry. Intervirology 2014; 57: 151-7. [CrossRef] Urban S, Bogomolov P, Voronkova N, et al. A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B. 65th Annual Meeting of AASLD; Boston MA, USA 2014.
  4. Nkongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014; 60: 723-31. [CrossRef] Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate co- transporting polypeptide (NTCP). Hepatology 2014; 59: 1726-37. [CrossRef] Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA- bound H3